Olnyd Trio 40 Tablet

Olnyd Trio 40 Tablet contains chlorthalidone, cilnidipine, and olmesartan medoxomil, a triple combination used in the management of hypertension. Chlorthalidone is a thiazide-like diuretic that reduces fluid volume, cilnidipine is a calcium channel blocker that relaxes vascular smooth muscle, and olmesartan medoxomil is an angiotensin II receptor blocker that prevents vasoconstriction. Together they provide complementary blood pressure lowering through three distinct mechanisms. Always use Olnyd Trio 40 Tablet exactly as directed by your doctor.

Olnyd Trio 40 Tablet is a fixed-dose triple antihypertensive combination targeting blood pressure through diuretic, calcium channel blocking, and renin-angiotensin system inhibitory mechanisms.

Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, increasing urinary sodium and water excretion. This reduces plasma volume and cardiac preload, lowering blood pressure.

Cilnidipine is a dual L-type and N-type calcium channel blocker. L-type blockade relaxes arterial vascular smooth muscle, reducing peripheral vascular resistance. N-type blockade additionally suppresses sympathetic noradrenaline release at nerve terminals, providing a more balanced antihypertensive effect with less reflex tachycardia compared to other dihydropyridine calcium channel blockers.

Olmesartan medoxomil is a prodrug that is converted to olmesartan after absorption. It selectively blocks AT1 angiotensin II receptors, preventing the vasoconstriction, aldosterone secretion, and sodium retention triggered by angiotensin II. This provides sustained blood pressure reduction and end-organ protection.

Together these three mechanisms provide additive and complementary antihypertensive effects, allowing effective blood pressure control with lower doses of each individual component.

The uses of Olnyd Trio 40 Tablet are as follows:

Hypertension

Olnyd Trio 40 Tablet is used to manage moderate to severe hypertension where monotherapy or dual therapy has not achieved adequate blood pressure control.

Hypertension with Volume Overload

Chlorthalidone addresses the fluid retention component of hypertension in susceptible patients.

Hypertension with Sympathetic Overactivity

Cilnidipine's N-type calcium channel blockade provides additional benefit in patients with high sympathetic tone.

Hypertension with Diabetic Nephropathy

Olmesartan provides renal protection alongside blood pressure control in patients with diabetic kidney disease.

Resistant Hypertension

The triple combination is particularly useful in patients whose blood pressure remains uncontrolled on dual therapy.

Here are the benefits of Olnyd Trio 40 Tablet:

• Triple Mechanism Blood Pressure Control: Addresses hypertension through diuresis, vascular smooth muscle relaxation, and renin-angiotensin system blockade simultaneously.

• Reduced Reflex Tachycardia: Cilnidipine's N-type calcium channel blockade suppresses sympathetic activation, minimising the heart rate increase seen with other calcium channel blockers.

• End-Organ Protection: Olmesartan provides renal and cardiovascular protection beyond blood pressure lowering.

• Improved Tolerability: Combining lower doses of three agents reduces the side effects associated with higher doses of any single agent.

• Convenient Once-Daily Dosing: Fixed-dose combination improves treatment adherence in patients requiring multiple antihypertensive agents.

Like all medicines, Olnyd Trio 40 Tablet may cause side effects in some individuals.

Common Side Effects

• Dizziness or Light-Headedness: Particularly on standing, due to blood pressure reduction.

• Increased Urination: Expected with the diuretic action of chlorthalidone.

• Peripheral Oedema: Ankle swelling may occur due to the vasodilatory effects of cilnidipine.

Uncommon Side Effects

• Electrolyte Disturbances: Chlorthalidone may cause hypokalaemia, hyponatraemia, or hypomagnesaemia.

• Headache: Mild headache may develop during early treatment.

• Fatigue: Some patients report tiredness during dose adjustment.

Serious Side Effects (Require Immediate Medical Attention)

• Severe Hypotension: Marked blood pressure drop, particularly after the first dose or in volume-depleted patients.

• Hyperkalaemia: Olmesartan may raise potassium levels, requiring monitoring particularly in renal impairment.

• Acute Renal Impairment: Olmesartan combined with diuretics may reduce renal perfusion in susceptible individuals.

• Severe Allergic Reaction: Swelling of the face, lips, or throat with difficulty breathing requires urgent medical care.

Always consult your doctor if side effects persist or worsen.

To ensure safe use:

• Use exactly as prescribed by your doctor.

• Usually taken orally once daily with or without food.

• Take at the same time each day for consistent blood pressure control.

• Do not discontinue without consulting your doctor.

• Rise slowly from sitting or lying positions to minimise dizziness.

Olnyd Trio 40 Tablet lowers blood pressure through three complementary mechanisms.

Chlorthalidone inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing urinary excretion of sodium and water. This reduces circulating blood volume and cardiac output, lowering blood pressure.

Cilnidipine blocks both L-type calcium channels in arterial smooth muscle, causing vasodilation and reduced peripheral resistance, and N-type calcium channels at sympathetic nerve terminals, suppressing noradrenaline release and reducing sympathetic vascular tone.

Olmesartan selectively and competitively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction, aldosterone release, and sodium retention. This produces sustained vasodilation and reduces both preload and afterload on the heart.

A few practical measures can help improve treatment outcomes and ensure safe use of Olnyd Trio 40 Tablet:

• Monitor blood pressure regularly: Home blood pressure monitoring helps assess treatment response and detect over or under treatment.

• Rise slowly from lying or sitting: Postural hypotension is more likely during early treatment or after dose adjustment.

• Maintain adequate fluid intake: Chlorthalidone increases urinary output; adequate hydration prevents excessive volume depletion.

• Avoid potassium supplements unless advised: Olmesartan may raise potassium levels; additional supplementation requires medical guidance.

• Do not stop treatment abruptly: Sudden discontinuation may cause rebound hypertension. Always consult your doctor before making changes.

Proper storage is important to maintain the stability and effectiveness of Olnyd Trio 40 Tablet:

• Store at room temperature: Keep away from heat, moisture, and direct sunlight.

• Keep in original packaging: Protects tablets from humidity and light.

• Keep out of reach of children: Store safely to prevent accidental ingestion.

• Check expiry before use: Do not use after the expiry date printed on the packaging.

Olnyd Trio 40 Tablet may generally be taken without strict dietary restrictions. However:

• Avoid excessive alcohol: Enhances blood pressure lowering and increases dizziness risk.

• Limit high-potassium foods if advised: Olmesartan may raise potassium; excessive dietary potassium may compound this in susceptible patients.

• Reduce dietary sodium: A low-sodium diet complements the antihypertensive effect of this combination.

Olnyd Trio 40 Tablet may interact with the following medicines:

• NSAIDs: May reduce the antihypertensive effects of olmesartan and chlorthalidone and increase renal impairment risk.

• Potassium-Sparing Diuretics: Combined use with olmesartan may cause significant hyperkalaemia.

• Lithium: Chlorthalidone reduces lithium excretion, raising the risk of lithium toxicity.

• Antidiabetic Medicines: Chlorthalidone may impair glycaemic control, requiring dose adjustments.

• Other Antihypertensives: Additive blood pressure lowering may cause excessive hypotension.

Olnyd Trio 40 Tablet should be used carefully in the following conditions:

• Renal Artery Stenosis: Olmesartan may precipitate acute renal failure in patients with bilateral renal artery stenosis.

• Gout: Chlorthalidone may raise uric acid levels and precipitate gout attacks.

• Hypokalaemia: Chlorthalidone-induced potassium loss requires monitoring and correction.

• Diabetes Mellitus: Chlorthalidone may impair glucose tolerance; blood glucose monitoring is advisable.

• Hyperaldosteronism: Olmesartan's mechanism may be less effective in primary hyperaldosteronism.

Usually taken as a single oral dose once daily as directed by your doctor. Dose depends on the specific formulation strength and the degree of blood pressure control required.

If a dose is missed, take it as soon as remembered. Do not double the dose to make up for a missed one.